Acadia Pharma (ACAD) Misses Q2 EPS by 14c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $26.20 +1.67%
EPS Growth %: -62.5%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
EPAC, SAR, KRUS, More
EPS Growth %: -62.5%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.63), $0.14 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $97 thousand versus the consensus estimate of $90 thousand.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance
- Freedom Broker Starts Holley (HLLY) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
